University of Goettingen   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Goettingen Germany (1734)

Organization Overview

First Clinical Trial
1995
NCT02378805
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Armin Goralczyk | Center of Neurological Medicine, Goettingen, Germany | Center of Operative Urology Bremen | Departement of Medical Statistics, University Medical Center Göttingen | Department of Cardiology and Pulmonolog - Universitaetsmedizin Goettingen - 37099 Goettingen, Germany | Department of Pharmacology, Klinikum Bremen Mitte, Bremen, Germany | Department of Psychiatry and Psychotherapy, Georg-August-University, Germany | Dept. of Clinical Pharmacology, Georg-August-University of Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany | Gastroenterology and Endocrinology, University Medicine of Goettingen | Georg-August-University | Herzzentrum Goettingen | Herzzentrum Goettingen, Cardiology and Pneumology | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Karsten Gavenis | Klinikum Bremen Mitte | Klinikum Bremen-Mitte, gGmbH | Klinikum Bremen-Mitte gGmbH, Medizinische Klinik I, Bremen, Germany | Medical Statistics, University Medicine of Goettingen | PFH Private Hochschule Göttingen Germany | Prof. Jürgen Brockmöller | Universitatsklinikum Gottingen | University Goettingen | University Hospital Goettingen | University Medical Center Göttingen | University Medical Center Goettingen | University Medical Center Goettingen, Department Nephrology and Rheumatology | University Medical Center Goettingen, Goettingen | University Medical Center Göttingen | University Medical Center Gottingen, Germany | University Medical Center Göttingen (UMG) | University medicine Goettingen | University of Goettingen | University of Göttingen

Active Ingredients

Drugs in Phase 4 Trials (16)

arctuvan (2 trials)

ferrous sulfate (1 trial)

fosfomycin (monurol) (1 trial)

galantamine (reminyl) (1 trial)

haloperidol (haldol) (2 trials)

ibuprofen (motrin) (2 trials)

lorazepam (ativan) (1 trial)

memantine (namenda) (2 trials)

nicotine (nicorette) (1 trial)

paroxetine (paxil) (1 trial)

quetiapine (seroquel) (2 trials)

ranibizumab (lucentis) (2 trials)

risperidone (risperdal) (1 trial)

sodium chloride (1 trial)

tromethamine (tham) (1 trial)

varenicline (chantix) (1 trial)

Drugs in Phase 3 Trials (16)

albutein (1 trial)

alemtuzumab (campath) (2 trials)

bevacizumab (avastin) (1 trial)

bicalutamide (casodex) (1 trial)

budesonide (rhinocort) (1 trial)

bupropion (wellbutrin) (1 trial)

chloroquine (1 trial)

goserelin (zoladex) (1 trial)

ibritumomab tiuxetan (zevalin) (2 trials)

idursulfase (elaprase) (1 trial)

ramipril (altace) (2 trials)

remdesivir (1 trial)

spironolactone (aldactone) (2 trials)

temozolomide (temodar) (1 trial)

tenecteplase (tnkase) (1 trial)

valproic acid (depakene) (1 trial)

Drugs in Phase 2 Trials (16)

basiliximab (simulect) (1 trial)

bendamustine (treanda) (1 trial)

cabozantinib (cometriq) (1 trial)

echitabplus-icp (1 trial)

epoetin (Epogen) (1 trial)

everolimus (zortress) (1 trial)

fasudil (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

fludeoxyglucose f-18 (1 trial)

mirabegron (myrbetriq) (1 trial)

mycophenolate (myfortic) (2 trials)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (2 trials)

simvastatin (zocor) (1 trial)

tacrolimus (prograf) (1 trial)

α-oxopropionsäure (1 trial)

Drugs in Phase 1 Trials (16)

acetaminophen (tylenol) (1 trial)

amitriptyline (elavil) (1 trial)

caffeine (3 trials)

codeine (Phenergan) (1 trial)

desvenlafaxine (pristiq) (1 trial)

fenoterol (1 trial)

metoprolol (lopressor) (1 trial)

midazolam (versed) (1 trial)

pantoprazole (protonix) (1 trial)

pravastatin (pravachol) (1 trial)

proguanil (1 trial)

sumatriptan (zecuity) (1 trial)

talinolol (1 trial)

thiamine (1 trial)

torsemide (demadex) (1 trial)

vorinostat (zolinza) (1 trial)

Drugs in Other Trials (2)

paricalcitol (zemplar) (1 trial)

sodium fluoride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Affective Symptoms (Phase 4)

Aggression (Phase 2)

Alcohol Drinking (Phase 2)

Alcoholism (Phase 2)

Alzheimer Disease (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 2)

Anemia, Iron-Deficiency (Phase 4)

Astrocytoma (Phase 3)

Carcinoma, Neuroendocrine (Phase 2)

Communicable Diseases (Phase 4)

Dementia (Phase 3)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 4)

Embolism (Phase 3)

Glioblastoma (Phase 3)

Glioma (Phase 3)

Heart Failure (Phase 4)

Heart Failure, Systolic (Phase 4)

Hypertrophy (Phase 2)

Hypertrophy, Left Ventricular (Phase 2)

Immunoblastic Lymphadenopathy (Phase 3)

Infarction (Phase 2)

Infections (Phase 4)

Lymphadenopathy (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Extranodal NK-T-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, T-Cell (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 3)

Macular Degeneration (Phase 4)

Mental Disorders (Phase 4)

Motor Neuron Disease (Phase 2)

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis II (Phase 3)

Myocardial Infarction (Phase 2)

Neoplasms, Neuroepithelial (Phase 3)

Nephritis, Hereditary (Phase 3)

Neuritis (Phase 2)

Neuroendocrine Tumors (Phase 2)

Obesity (Phase 2)

Optic Neuritis (Phase 2)

Panic Disorder (Phase 4)

Prostatic Neoplasms (Phase 3)

Psychotic Disorders (Phase 4)

Pulmonary Embolism (Phase 3)

Recurrence (Phase 2)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Schizophrenia (Phase 4)

Shock (Phase 3)

Shock, Cardiogenic (Phase 2)

Shock, Septic (Phase 3)

Sinusitis (Phase 3)

Syndrome (Phase 3)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 66